Apollo Life Sciences

Apollo Life Sciences was an Australian biotechnology company focused on the development and commercialization of human-expressed proteins for therapeutic and cosmeceutical applications. The company specialized in creating optimized versions of naturally occurring human proteins, such as TNF-alpha inhibitors and growth factors, using its proprietary mammalian cell expression systems. Their primary research focused on improving the delivery of these proteins through non-invasive methods, including needle-free topical and oral formulations. Despite listing on the Australian Securities Exchange and advancing several candidates into early-stage clinical trials, the company faced significant financial difficulties and entered liquidation in the late 2000s.